<DOC>
	<DOCNO>NCT01871194</DOCNO>
	<brief_summary>This study aim evaluate use rivaroxaban short term safety use patient new indication prevention stroke systemic embolism patient non-valvular atrial fibrillation , treatment deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) prevention recurrent DVT PE . Any adult patient start care team rivaroxaban alternative anticoagulant specify indication study period eligible take part . A questionnaire complete care team patient start treatment 12 week later . The care team complete questionnaires use information patient 's medical note , ask patient directly . If participant adverse event 12 week period , may ask patient 's care team fill follow questionnaire . No examination test perform . Patients recruit study clinical decision prescribe rivaroxaban alternative anticoagulant make , prescribe behaviour alter study . It observational , non-interventional study cover whole England Wales .</brief_summary>
	<brief_title>An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study ( SCEM ) Monitor Safety Utilization Rivaroxaban ( XareltoÂ® ) .</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>age 18 year study start index date study start sign , informed consent patient treat DVT PE patient nonvalvular AF ( one risk factor ) treat prevention stroke systemic embolism use univalent direct thrombin inhibitor direct factor Xa inhibitor use anticoagulant therapy vitamin K antagonists record within one year prior index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>